Systemic and primary cutaneous anaplastic large cell lymphoma: Clinical features, morphological spectrum, and immunohistochemical profile

Kanwardeep Singh Kwatra; Preethi A.M. Paul; Nalini Calton; Joseph M. John; James D. Cotelingam

doi:10.4103/2278-330X.214575

South Asian Journal of Cancer, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · South Asian J Cancer 2017; 06(03): 129-131
DOI: 10.4103/2278-330X.214575

ORIGINAL ARTICLE : Leukemia and Lymphoma

Systemic and primary cutaneous anaplastic large cell lymphoma: Clinical features, morphological spectrum, and immunohistochemical profile

Kanwardeep Singh Kwatra

Department of Pathology, Christian Medical College and Hospital, Ludhiana, Punjab

,

Preethi A.M. Paul

Department of Pathology, Christian Medical College and Hospital, Ludhiana, Punjab

,

Nalini Calton

Department of Pathology, Christian Medical College and Hospital, Ludhiana, Punjab

,

Joseph M. John

Department of Clinical Hematology, Hemato-Oncology and Bone Marrow (Stem Cell) Transplant Unit, Christian Medical College and Hospital, Ludhiana, Punjab

,

James D. Cotelingam

Department of Pathology, Louisiana State University Health Sciences Center, Shreveport, LA 71103

› Institutsangaben

Abstract

als PDF herunterladen

Abstract

Background: T-cell lymphomas with anaplastic morphology typically comprise of anaplastic lymphoma kinase positive, anaplastic large cell lymphoma (ALK+ ALCL), ALK-negative ALCL (ALK- ALCL), and primary cutaneous ALCL (PC-ALCL). However, other entities such as diffuse large B-cell lymphoma, peripheral T-cell lymphoma, Hodgkin lymphoma, and undifferentiated carcinoma can also show similar anaplastic features. Aims: To study the clinical features and histological spectrum of ALCL and emphasize the role of immunohistochemistry (IHC) in their diagnosis and categorization. Setting and Design: Eight cases of ALCL diagnosed over a period of 4 years were selected for the study. Materials and Methods: Histopathological review and IHC was performed on all cases. Two ALK+ ALCL cases were tested by fluorescent in situ hybridization (FISH) for t(2;5)(p23;q35). Results: There were four cases of ALK+ ALCL and two each of ALK- ALCL and PC-ALCL. Histologically, all the subtypes showed pleomorphic and “hallmark” cells with strong CD30 expression and variable loss of T-cell antigens. One case of PC-ALCL was leukocyte common antigen (LCA) negative. Epithelial membrane antigen was positive in all the six systemic ALCL cases. Two cases tested for t(2;5)(p23;q35) by FISH were positive. Conclusions: Diagnosis of ALCL is based on recognizing the key morphological features, especially the presence of “hallmark” cells. IHC is essential for confirmation of diagnosis and excluding other malignancies with anaplastic morphology. The inclusion of CD30 in the initial IHC panel will help identify LCA negative cases and avoid misdiagnosis.

Key words

Anaplastic large cell lymphoma - anaplastic lymphoma kinase-1 - CD30 - epithelial membrane antigen - immunohistochemistry - non-Hodgkin lymphoma - T-cell

PDF (725 kb)

Referenzen

References
1 Delsol G, Falini B, Muller-Hermelink HK, Campo E, Jaffe ES, Gascoyne RD, et al. Anaplastic large cell lymphoma (ALCL), ALK-positive. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haemopoietic and Lymphoid Tissue. 4^th ed. Lyon: International Agency for Research on Cancer (IARC); 2008. p. 312-6.
2 Mason DY, Harris NL, Delsol G, Stein H, Campo E, Kinney MC, et al. Anaplastic large cell lymphoma, ALK-negative. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haemopoietic and Lymphoid Tissue. 4^th ed. Lyon: International Agency for Research on Cancer (IARC); 2008. p. 317-9.
3 Ralfkiaer E, Willemze R, Paulli M, Kadin ME. Primary cutaneous CD30-positive T-cell lymphoproliferative disorders. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors. WHO Classification of Tumours of Haemopoietic and Lymphoid Tissue. 4^th ed. Lyon: International Agency for Research on Cancer (IARC); 2008. p. 300-1.
4 Inghirami G, Pileri SA; European T-Cell Lymphoma Study Group. Anaplastic large-cell lymphoma. Semin Diagn Pathol 2011;28:190-201.
5 Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the International Peripheral T-Cell Lymphoma Project. Blood 2008;111:5496-504.
6 Burg G, Kempf W, Cozzio A, Feit J, Willemze R, Jaffe ES, et al. WHO/EORTC classification of cutaneous lymphomas 2005: Histological and molecular aspects. J Cutan Pathol 2005;32:647-74.
7 Calzado-Villarreal L, Polo-Rodríguez I, Ortiz-Romero PL. Primary cutaneous CD30+ lymphoproliferative disorders. Actas Dermosifiliogr 2010;101:119-28.
8 Gustafson S, Medeiros LJ, Kalhor N, Bueso-Ramos CE. Anaplastic large cell lymphoma: Another entity in the differential diagnosis of small round blue cell tumors. Ann Diagn Pathol 2009;13:413-27.
9 Amin HM, Lai R. Pathobiology of ALK+ anaplastic large-cell lymphoma. Blood 2007;110:2259-67.
10 Schmitz N, Trümper L, Ziepert M, Nickelsen M, Ho AD, Metzner B, et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group. Blood 2010;116:3418-25.